高亲和力新抗原与肝细胞癌预后及CD39+CD8+ T细胞抗肿瘤活性相关
本研究基于56例肝细胞癌患者全外显子测序数据,以MHC-I算法预测突变型IC50<50 nM的新抗原为高亲和力新抗原(HAN)。结果显示HAN值与总生存期(p=0.0199)的相关性优于肿瘤突变负荷(p=0.7505)或新抗原总数(p=0.2297),且HAN高组CD39+CD8+肿瘤浸润淋巴细胞频率更高、抗肿瘤活性更强,抗PD-1治疗后预后更好。
要点
- HAN值与HCC患者总生存期正相关,优于TMB或新抗原总数。
- HAN高组CD39+CD8+ TILs频率更高且抗肿瘤活性更强。
- HAN高组患者抗PD-1治疗预后优于HAN低组。
核心结论
- HAN值与HCC患者更好的总生存期正相关。
- HAN通过激活肿瘤反应性CD39+CD8+ T细胞触发抗肿瘤活性。
- HAN高组患者从抗PD-1治疗中获益多于HAN低组。
研究设计与样本
- 回顾性分析56例HCC患者全外显子测序数据,用pVAC工具结合MHC-I算法预测新抗原。
- 突变型IC50<50 nM的新抗原定义为高亲和力新抗原(HAN)。
- 按HAN值中位数将患者分为HAN高组和低组,分析总生存期。
- 建立自体类器官杀伤模型评估HAN的抗肿瘤活性。
主要发现
- HAN值与OS相关性(p=0.0199)优于TMB(p=0.7505)或新抗原总数(p=0.2297)。
- HAN值与CD39+CD8+ TILs频率正相关。
- 在CD39+CD8+ TILs中鉴定出HAN特异性CD8+ T细胞,HAN高组抗肿瘤活性优于低组。
- HAN高组鉴定出更多有效HAN肽段。
- 新鲜肿瘤流式显示CD39+PD-1intCD8+ TILs呈效应表型,HAN高组抗肿瘤活性更强。
关键数值与推荐
- 高亲和力新抗原定义为突变型IC50<50 nM。
- 按HAN值中位数分组比较预后。
- HAN值与OS相关p=0.0199,TMB与OS相关p=0.7505,新抗原与OS相关p=0.2297。
临床怎么用
- HAN值或可作为HCC预后评估和抗PD-1治疗获益预测的生物标志物。
- HAN高组患者可能更适合抗PD-1免疫治疗。
- 靶向CD39+CD8+ T细胞或HAN肽段疫苗可能是HCC个性化治疗新策略。
局限性
- 样本量较小(n=56)。
- HAN定义依赖MHC-I算法预测,需实验验证。
- 单中心研究,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: It remains controversial whether tumour mutational burden (TMB) or neoantigens are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the function of TMB or neoantigens in antitumour immunotherapy. DESIGN: Neoantigens of patients (n=56) were analysed by pVAC tools with major histocompatibility complex-1 (MHC-I) algorithms based on whole exome sequencing and neoantigens with mutant type IC50 <50 nM were defined as high-affinity neoantigens (HANs). Patients were segregated into HAN-high/low groups by median of HAN value, and overall survival (OS) was analysed. Autologous organoid killing model was developed to clarify the antitumour activity of HANs. RESULTS: The value of HAN showed a better correlation with OS (p=0.0199) than TMB (p=0.7505) or neoantigens (p=0.2297) in patients with HCC and positively correlated with the frequency of CD39+CD8+ tumour infiltrating lymphocytes (TILs). Furthermore, HAN-specific CD8+ T cells were identified in CD39+CD8+ TILs, which showed better antitumour activity in HAN-high versus HAN-low group. In addition, more effective HAN peptides were identified in HAN-high versus HAN-low group. Besides, flow cytometry data showed that in fresh tumour, CD39+PD-1intCD8+ TILs displayed an effector phenotype and stronger antitumour activity in HAN-high versus HAN-low group. More importantly, patients in HAN-high versus HAN-low group showed a better prognosis after anti-PD-1 therapy. CONCLUSIONS: Our study first demonstrates that HAN value positively correlates with better OS in patients with HCC. HANs trigger antitumour activity by activating tumour-reactive CD39+CD8+ T cells, and patients in HAN-high group benefited more from anti-PD-1 therapy than HAN-low group. These findings may provide a novel strategy for personalised antitumour therapies for HCC.
引用
- Liu T, Tan J, Wu M, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells. Gut. 2020. PMID: 33262196. doi:10.1136/gutjnl-2020-322196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。